>>Signaling Pathways>> Immunology/Inflammation>> Interleukin Related>>RP-54745

RP-54745

Catalog No.GC31804

RP-54745는 대식세포 자극과 인터루킨-1 생산의 억제제이자 잠재적인 항류마티스 화합물이다.

Products are for research use only. Not for human use. We do not sell to patients.

RP-54745 Chemical Structure

Cas No.: 135330-08-4

Size 가격 재고 수량
1mg
US$92.00
재고 있음
5mg
US$184.00
재고 있음
10mg
US$313.00
재고 있음
20mg
US$552.00
재고 있음

Tel:(909) 407-4943 Email: sales@glpbio.com

고객 리뷰

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

RP 54745 is an inhibitor of macrophage stimulation and interleukin-1 production, and a potential antirheumatic compound.

RP 54745 diminishes LPS-induced interleukin-1 (IL-1) production by murine peritoneal macrophages[1].

RP 54745 (5 mg/kg) is effective at moderating oral doses in different mouse models of induced arthritis and in the MRL/lpr mice, genetically predisposed to develop an autoimmune pathology including arthritic disorders. The clinical status of the MRL mice, and several of their disturbed biochemical and immunological parameters, improved after a 3-month treatment with RP 54745[2].

[1]. Folliard F, et al. RP 54745, a potential antirheumatic compound. I. Inhibitor of macrophage stimulation and interleukin-1 production. Agents Actions. 1992 May;36(1-2):119-26. [2]. Folliard F, et al. RP 54745, a potential antirheumatic compound. II. In vivo properties in different animal models. Agents Actions. 1992 May;36(1-2):127-35.

리뷰

Review for RP-54745

Average Rating: 5 ★★★★★ (Based on Reviews and 27 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for RP-54745

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.